Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rap1b siRNA
- Development stage
- Preclinical
- Lead developer
- Morehouse School of Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
rap1b siRNA is a small interfering RNA designed to silence the expression of Rap1b, a small GTPase of the Ras superfamily. In the context of glioblastoma (GBM), Rap1b is highly expressed in glioma stem-like cells (GSCs) and plays a critical role in maintaining stemness and promoting angiogenesis. By knocking down Rap1b, this siRNA inhibits Notch1 and VEGFR2 signaling pathways, leading to reduced cell proliferation, induction of apoptosis, and G2/M phase arrest. Research indicates that Rap1b knockdown also decreases the expression of stemness markers such as CD133, ALDH1, and SOX2, and disrupts a positive feedback loop with VEGFR2 that drives tumor angiogenesis. It is currently being investigated as a potential therapeutic strategy to overcome treatment resistance and disrupt GSC-driven growth in malignant brain tumors.
- Other names
- Rap1b knockdownRap-1b knockdownRap 1b knockdownsiRNA targeting Rap1b
02
Targets
RAP1
Beyond the preview
Go deeper on rap1b siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rap1b siRNA.